Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary.
Harry E Fuentes BaynePashtoon Murtaza KasiLi MaLowell L HartJenna WongDavid R SpigelCatherine A SchnabelJames A ReevesThorvardur R HalfdanarsonKai TreunerF Anthony GrecoPublished in: JCO precision oncology (2024)
This retrospective analysis supports incorporating CancerTYPE ID into the evaluation for patients with CUP to help determine the tissue of origin and identify actionable genetic alterations. This approach may allow more patients with CUP to benefit from site-specific FDA-approved targeted therapies or enrollment into clinical trials.
Keyphrases
- clinical trial
- genome wide
- copy number
- papillary thyroid
- machine learning
- deep learning
- squamous cell
- high throughput
- single cell
- squamous cell carcinoma
- drug administration
- stem cells
- healthcare
- phase ii
- single molecule
- randomized controlled trial
- mesenchymal stem cells
- gene expression
- open label
- transcription factor
- phase iii
- double blind
- clinical evaluation